187 related articles for article (PubMed ID: 24572052)
1. Antitumor effects of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model.
Lee HG; Baek JW; Shin SJ; Kwon SH; Cha SD; Park WJ; Chung R; Choi ES; Lee GH; Cho CH
Reprod Sci; 2014 Sep; 21(9):1153-60. PubMed ID: 24572052
[TBL] [Abstract][Full Text] [Related]
2. Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin.
Kim DC; Ramachandran S; Baek SH; Kwon SH; Kwon KY; Cha SD; Bae I; Cho CH
Reprod Sci; 2008 Jul; 15(6):552-8. PubMed ID: 18487228
[TBL] [Abstract][Full Text] [Related]
3. Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.
Koohestani F; Qiang W; MacNeill AL; Druschitz SA; Serna VA; Adur M; Kurita T; Nowak RA
Hum Reprod; 2016 Jul; 31(7):1540-51. PubMed ID: 27130615
[TBL] [Abstract][Full Text] [Related]
4. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.
Raju U; Nakata E; Mason KA; Ang KK; Milas L
Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657
[TBL] [Abstract][Full Text] [Related]
7. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor cell proliferation in human uterine leiomyomas by vitamin D via Wnt/β-catenin pathway.
Corachán A; Ferrero H; Aguilar A; Garcia N; Monleon J; Faus A; Cervelló I; Pellicer A
Fertil Steril; 2019 Feb; 111(2):397-407. PubMed ID: 30458994
[TBL] [Abstract][Full Text] [Related]
13. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells.
Mihara M; Shintani S; Nakashiro K; Hamakawa H
Oral Oncol; 2003 Jan; 39(1):49-55. PubMed ID: 12457721
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer.
Chung KH; Cho IR; Paik WH; Kim YT; Lee SH; Ryu JK
Anticancer Res; 2024 Mar; 44(3):1097-1108. PubMed ID: 38423644
[TBL] [Abstract][Full Text] [Related]
17. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Tan AR; Swain SM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
[TBL] [Abstract][Full Text] [Related]
18. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53.
Shime H; Kariya M; Orii A; Momma C; Kanamori T; Fukuhara K; Kusakari T; Tsuruta Y; Takakura K; Nikaido T; Fujii S
J Clin Endocrinol Metab; 2002 Dec; 87(12):5610-7. PubMed ID: 12466360
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
20. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.
Wang LM; Ren DM
Mini Rev Med Chem; 2010 Oct; 10(11):1058-70. PubMed ID: 21047304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
